Baiyao Technology

Baiyao Technology (百曜科技) is an AI virtual cell (AIVC) platform company founded in 2023 that builds foundation models to simulate and predict cellular behavior under different interventions—such as drugs, gene editing, and environmental changes—using large-scale single-cell multi-omics data . The company positions its technology as a new underlying tool for drug R&D, cell therapy, and disease research, aiming to bring life-system changes into the "computable era" .

On funding: Baiyao raised a seed round in the tens of millions of RMB led by FreeS Fund, with Shunxi Capital participating ; a later round in the same range was co-invested by the Yunqi-SJTU AI Angel Fund ; and its most recent disclosed financing was led by China Reform Fund (the venture capital arm of state-owned China Guoxin) . FreeS Fund's Ma Rui has identified Baiyao as part of its AI for science portfolio, alongside AI drug discovery .